All In Biotech

Drug Trial Radar · NCT02199691

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,715 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,715

Actual

Start

Jul 22, 2014

Primary completion

Oct 2, 2015

Study completion Oct 2, 2015

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jul 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine. Primary objective: * To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine when MenACYW Conjugate vaccine was given alone compared to those when MENVEO vaccine was given alone. Secondary objective: * To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with Tdap and HPV vaccines, compared to those when it was given alone. * To evaluate the antibody responses to the antigens present in Tdap vaccine, when Tdap vaccine was given concomitantly with MenACYW Conjugate vaccine and HPV vaccine, compared to those when Tdap vaccine was given with HPV vaccine only. * To evaluate the antibody responses to the antigens present in HPV vaccine after the 3-dose series, when the first dose of HPV vaccine is given concomitantly with MenACYW Conjugate vaccine and Tdap vaccine, compared to those when the first dose of HPV vaccine is given with Tdap vaccine only. Observational objective: * To describe the safety profile of MenACYW Conjugate vaccine, compared to that of the licensed vaccine MENVEO®, and when MenACYW Conjugate vaccine was given with Tdap and HPV vaccines.

Conditions

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections

Interventions

  • Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate VaccineBiological

    0.5 milliliter (mL), Intramuscular (IM)

  • Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate VaccineBiological

    0.5 mL, IM

  • Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine AdsorbedBiological

    0.5 mL, IM

  • GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, RecombinantBiological

    0.5 mL, IM

  • Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate VaccineBiological

    0.5 mL, Intramuscular (IM)

  • Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine AdsorbedBiological

    0.5 mL, IM

  • GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, RecombinantBiological

    0.5 mL, IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® VaccineTime frame: Day 30 (post-vaccination)

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Downey, California

  • Site not named

    San Diego, California

  • Site not named

    Miami Beach, Florida

  • Site not named

    Wichita, Kansas

  • Site not named

    Bardstown, Kentucky

  • Site not named

    Nicholasville, Kentucky

  • Site not named

    Columbia, Maryland

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Cleveland, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Norman, Oklahoma

  • Site not named

    Erie, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Kingsport, Tennessee

  • Site not named

    Tullahoma, Tennessee

  • Site not named

    Layton, Utah

  • Site not named

    Orem, Utah

  • Site not named

    Payson, Utah

  • Site not named

    Provo, Utah

  • Site not named

    Roy, Utah

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Salt Lake City, Utah

  • Site not named

    South Jordan, Utah

  • Site not named

    Spanish Fork, Utah

  • Site not named

    Syracuse, Utah

  • Site not named

    West Haven, Utah

  • Site not named

    West Jordan, Utah

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Midlothian, Virginia

  • Site not named

    Spokane, Washington

  • Site not named

    Spokane, Washington

  • Site not named

    San Juan, PR, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.